arrow
J

Jens Klotsche

deutsches rheuma-forschungszentrum
H指数:54
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies

幼年特发性关节炎相关葡萄膜炎的血清学生物标志物:ANA滴度、ANA AC-30染色模式和预折叠蛋白5抗体

2026-05-260
OA
What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort

青少年系统性硬化症的治疗模式:国际队列研究的结果

2026-05-260
PRE
Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis

选择性清除自身反应性浆细胞作为治疗乙酰胆碱受体抗体阳性重症肌无力的新策略

2026-04-010
PRE
Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial

Daratumumab治疗系统性红斑狼疮: 一项单臂2期试验

2026-02-030
OAAI
Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis

纤维化间质性肺病患者目标导向管理的风险分层指导:一项基于登记研究的分析

2026-01-190
PRE
Compositional patterns of device-measured movement behaviour in juvenile idiopathic arthritis: results from the multicentre ActiMON study

设备测量运动行为在幼年特发性关节炎中的构成模式:多中心ActiMON研究的结果

2025-12-170
OAAI
Infant-onset juvenile idiopathic arthritis: a multicentre retrospective study

婴儿期起病的幼年特发性关节炎:一项多中心回顾性研究

2025-11-010
PRE
Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies

使用PCSK9单克隆抗体的心血管风险极高的患者的治疗持久性,降脂和3年临床结果

2025-08-040
OA
Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study

幼年特发性关节炎(JIA)患儿的葡萄膜炎病程:来自一项前瞻性多中心初始队列研究(ICON-JIA研究)中 Newly diagnosed patients with JIA 新诊断患者的5年随访数据

2025-03-200
OA
Clinical Presentation and Course of Pulmonary Involvement in Chronic Nonbacterial Osteomyelitis

慢性非细菌性骨髓炎的肺部受累的临床表现和病程

2025-01-280
OAAI
Late Breaking Abstract- Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
2024-10-300
PRE